Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this multicenter, pilot, open-label, Phase II clinical trial is to discover if
Everolimus(RAD001) is safe and effective in people who have advanced kidney cancer (renal
cell carcinoma - RCC).
Since 2002, Everolimus has been studied in more than 2500 patients with various types of
cancer as a single agent (a drug that is used alone to treat the cancer) or in combination
with a number of well known anticancer therapies. Various studies, in animals such as in mice
with cancer and in humans with cancer have shown that Everolimus can slow the growth of
cancer.
Everolimus will be taken in pill form by mouth daily for 3-5 weeks followed by surgery to
remove the effected kidney. After 2-4 weeks following the surgery, Everolimus will be resumed
at the same dose.